Autoimmune Disease Diagnostics Industry is anticipated to register 6.6% CAGR between 2022 and 2030 due to growing patient awareness and several initiatives taken by government and private organizations

SELBYVILLE, Del., July 13, 2022 /PRNewswire/ — The autoimmune disease diagnostics market value is expected to surpass USD 2 billion by 2030, according to a new research report by Global Market Insights Inc.

Autoimmune diseases occur because the autoimmune cells in the body fail to differentiate between self and non-self and end up exerting immunogenic response towards the body’s own cells. Several scientific and technological advancements have led to accurate and fast diagnostic methods in analyzing autoimmune disorders. MiRNAs regulate the gene expression. MiRNAs are important participants in many biological processes that control the adaptive immune systems’ innate and adaptive immune cell formation, maturation, and activation.

Request for a sample of this research report @ https://www.gminsights.com/request-sample/detail/618

Systemic autoimmune disease segment is set to cross USD 618 million by 2030. This is attributed to rising prevalence of autoimmune diseases such as systemic lupus erythematosus (SLE). For instance, as per data shared by the NCBI, in its 2021 report suggests that the rate of incidence of SLE is close to 0.74 to 1 person per 10,000. The women in age group of 15-44 years are more susceptible to SLE, as per a report cited by the CDC.

Some major findings of the autoimmune disease diagnostics market report include:

  • Growing prevalence of autoimmune diseases will drive the market size.
  • Technological developments in autoimmune disease diagnostics are anticipated to amplify the business revenue.
  • Supportive government policies for research activities on autoimmune diseases will boost the market forecasts.
  • Competitors are focusing on strategic product launches, partnerships, and geographical expansion to gain significant revenue share and cater to larger customer base.

Browse key industry insights spread across 190 pages with 292 market data tables & 17 figures & charts from the report, “Autoimmune Disease Diagnostics Market Analysis By Disease Type (Systemic Autoimmune Disease {Rheumatoid Arthritis, Systemic Lupus Erythematosus (SLE), Psoriasis, Multiple Sclerosis}, Localized Autoimmune Disease {Inflammatory Bowel Disease, Type 1 Diabetes, Thyroid), Test Type (Antinuclear Antibody Tests, Autoantibody Tests, C-reactive Protein (CRP), Complete Blood Count (CBC), Urinalysis), End-use (Hospitals, Diagnostic Centers), Industry Analysis Report, Regional Outlook, Application Potential, Competitive Market Share & Forecast, 2022 – 2030” in detail along with the table of contents:

https://www.gminsights.com/industry-analysis/autoimmune-disease-diagnostics-market 

Autoimmune disease diagnostics market from complete blood count (CBC) segment surpassed USD 94 million in 2021 and is projected to grow at a CAGR of 6.5% during the projected timeline. This is owing to the increasing adoption of lab automation technology in the developed regions such as U.S. and Europe. A complete blood count (CBC) is a blood test used to assess the general health and find a range of ailments, such as leukemia, anemia, and other infections. Moreover, rising awareness about the detection and management of the autoimmune diseases have added to the growth of the segment.

Diagnostics center segment exceeded USD 445 million in 2021. This is due to the feasible medical coverage and availability of advanced autoimmune diagnostics technology that promotes patient satisfaction and convenience. Diagnostics centers are seeing an increase in the number of patients seeking autoimmune disease diagnosis. Improving circumstances associated with diagnostic procedures in these facilities can enhance the segment revenue. 

China autoimmune disease diagnostics market is likely to witness 8.5% CAGR from 2022 to 2030. This is attributed to the high prevalence of autoimmune diseases, technological advancements, and supportive government policies in the country. Systemic lupus erythematosus (SLE) is increasingly prevalent in China affecting the nervous systems resulting in adoption of autoimmune disease diagnostics therapy. Furthermore, novel product launches in the country are expected to fuel the business landscape. Supportive government policies and increasing awareness regarding autoimmune disease diagnostics among people in China will augment the market outlook.

Request for customization of this research report @ https://www.gminsights.com/roc/618

Some of the major players operating in the autoimmune disease diagnostics market are Abbott Laboratories, Bio-rad Laboratories, F. Hoffmann-la Roche, Thermo Fisher Scientific, and EUROIMMUN Medizinische Labordiagnostika AG (Perkin Elmer). 

About Global Market Insights

Global Market Insights Inc., headquartered in Delaware, U.S., is a global market research and consulting service provider, offering syndicated and custom research reports along with growth consulting services. Our business intelligence and industry research reports offer clients with penetrative insights and actionable market data specially designed and presented to aid strategic decision making. These exhaustive reports are designed via a proprietary research methodology and are available for key industries such as chemicals, advanced materials, technology, renewable energy, and biotechnology.

Contact Us:

Arun Hegde
Corporate Sales, USA
Global Market Insights Inc.
Phone: 1-302-846-7766
Toll Free: 1-888-689-0688
Email: [email protected] 

Photo: https://mma.prnewswire.com/media/1858392/Autoimmune_Disease_Diagnostics_Market.jpg
Logo: https://mma.prnewswire.com/media/661916/GMI.jpg

SOURCE Global Market Insights Inc.